Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1624 1625 1626
This examiner grants 68% of resolved cases
Susanna Moore is an examiner in Tech Center 1600 and Art Unit 1624. She has 1262 resolved cases, resulting in an allowance rate of 68.1 percent. This 68.1 percent rate indicates a generally favorable outcome for many applicants. The median days to allowance is 1060.
The interview lift for this examiner is 31.6 percent. This 31.6 percent lift indicates that interviews are a highly effective method for moving cases toward allowance. When compared to the 68.1 percent allowance rate, the 31.6 percent lift shows that direct engagement provides a clear advantage. Practitioners should factor the 1060-day median pendency into their planning for Art Unit 1624.
With 1262 resolved cases, the examiner's data provides a very robust baseline for applicants. The 68.1 percent allowance rate and the 1060-day timeline are key indicators of her prosecution style. The 31.6 percent interview lift is an important tactical consideration for any applicant seeking to navigate the 1060-day process efficiently.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18283395 | ALGOSTATIC AGENTS FOR PREVENTING TRANSITION FROM ACUTE TO CHRONIC PAIN | Non-Final OA | The Regents of the University of California |
| 17753902 | METHOD OF MAKING AND/OR ISOLATING ISOIDIDE, COMPRISING SELECTIVE ESTERIFICATION OF A MIXTURE OF DIANHYDROHEXITOL ISOMERS | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18869346 | NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF | Non-Final OA | The Johns Hopkins University |
| 17911388 | METHODS OF CONTROLLING OR PREVENTING INFESTATION OF PLANTS BY THE PHYTOPATHOGENIC MICROORGANISM CORYNESPORA CASSIICOLA, CERCOSPORA SOJINA AND/OR CERCOSPORA KIKUCHII | Final Rejection | SYNGENTA CROP PROTECTION AG |
| 18905925 | DEUTERATED DERIVATIVES OF RUXOLITINIB | Final Rejection | Sun Pharmaceutical Industries, Inc. |
| 18078571 | DEUTERATED DERIVATIVES OF RUXOLITINIB | Final Rejection | Sun Pharmaceutical Industries, Inc. |
| 17906604 | TRICYCLIC P2-LIGAND CONTAINING POTENT HIV-PROTEASE INHIBITORS | Final Rejection | Purdue Research Foundation |
| 17758492 | TARGETED STEROID COMPOUNDS | Non-Final OA | Purdue Research Foundation |
| 18871590 | CRYSTALLINE FORMS OF AN AKRIC3 DEPENDENT KARS INHIBITOR | Non-Final OA | Novartis AG |
| 18685194 | SULFONYL-TRIAZOLES USEFUL AS COVALENT KINASE LIGANDS | Final Rejection | University of Virginia Patent Foundation |
| 18366544 | OXA- IBOGAINE INSPIRED ANALOGUES FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | Non-Final OA | The Trustees of Columbia University in the City of New York |
| 18017000 | IBOGAINE ANALOGS AS THERAPEUTICS FOR NEUROLOGICAL AND PSYCHIATRIC DISORDERS | Final Rejection | The Trustees of Columbia University in the City of New York |
| 18038579 | ENANTIOSELECTIVE ALKENYLATION OF ALDEHYDES | Final Rejection | AMGEN INC. |
| 18277765 | SMALL MOLECULE ALLOSTERIC MODULATORS OF CLASS B GPCR, THE PTHR, AND METHOD TO IDENTIFY THEM | Final Rejection | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 17912429 | COMPOSITIONS AND METHODS FOR TREATMENT OF PATHOLOGIC PAIN ASSOCIATED WITH MALIGNANT GROWTH DISORDER | Final Rejection | Duke University |
| 18624295 | METHOD FOR PRODUCING COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Final Rejection | EA PHARMA CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy